Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Chordal Repair for Transcatheter Mitral Valve Repair (TMVr)

A legfontosabb adatok

Ki végzi
Pipeline Medical
Hol
Grúzia, Paraguay és Szerbia4 helyszín, 3 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
7 fő vett részt
Kezdés
2022. márc. 18.
Befejezés
2024. máj. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Transcatheter implantation of chordal repair system
A regiszteradat frissítve
2024. október 15.

Ki vehet részt

Életkor
30 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 44 feltétel megnézéseKevesebb

Ki vehet részt

  • Presence of moderate to severe Mitral regurgitation as read on an echocardiographic study performed within 60 days prior to procedure
  • Estimated post-ePTFE chordae tendineae implantation coaptation surface is adequate in the judgment of the operating physician and the patient eligibility committee
  • Degenerative mitral valve disease
  • Patients who have been evaluated and no contraindication has been found for open heart surgery OR candidates for mitral valve surgery who, according to current guidelines, are at elevated surgical risk AND for whom transcatheter therapy is deemed more appropriate than open heart surgery in the judgement of the Site Heart Team

Ki nem vehet részt

  • Mitral annular diameter >45mm in any dimension. Left Ventricular End Diastolic Diameter (LVEDD) > 65mm. Left Ventricular End Systolic Dimension (LVESD) > 55 mm assessed by site based on a transthoracic echocardiographic (TTE) obtained within 90 days prior to subject enrollment
  • Coronary artery bypass grafting (CABG) within 30 days prior to subject's consent
  • Percutaneous coronary intervention within 30 days prior to subject's consent
  • Carotid surgery within 30 days prior to subject's consent
  • Implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) within the last 30 days prior to subject's consent
  • Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure
  • Status 1 heart transplant or prior orthotopic heart transplantation
  • Chronic Steroid Therapy
  • Cerebrovascular accident within 30 days prior to subject's consent
  • Currently participating in an investigational drug or another device study
  • Previously implanted prosthetic mitral valve or annuloplasty ring/band
  • Anatomical ineligibility to the investigational device
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Estimated pulmonary artery systolic pressure (PASP) > 70 mmHg assessed by site based on echocardiography or right heart catheterization
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, ischemic or non-ischemic Functional mitral regurgitation or any other structural heart disease causing heart failure
  • Hemodynamic instability requiring inotropic support or mechanical heart assistance
  • Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction
  • Tricuspid valve disease requiring surgery
  • Aortic valve disease requiring surgery or TAVI
  • Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
  • Life expectancy < 12 months due to non-cardiac conditions
  • Active infections requiring current antibiotic therapy
  • Condition that prevents transfemoral access
  • Known hypersensitivity or contraindication to procedural, post procedural medication (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or titanium
  • Creatine Kinase-MB (CK-MB) obtained within prior 14 days > local laboratory Upper Limit of Normal (ULN)
  • Left Ventricular Ejection Fraction (LVEF) is < 30% (within 90 days prior to subject enrollment, assessed by the site using any one of the following methods: echocardiography, contrast left ventriculography, gated blood pool scan or cardiac magnetic resonance imaging (MRI))
  • Chronic Kidney Disease with a baseline serum creatinine > 1.5mg/dL
  • Age <30/40 or > 85 years
  • Presence of any of the following:
  • Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)
  • Hemodynamic instability defined as systolic pressure < 90 mmHg with or without afterload reduction, cardiogenic shock or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device
  • Severe symptomatic carotid stenosis (> 70 % via ultrasound)
  • Pregnant or planning pregnancy within next 12 months
  • Severe organic lesions with mitral chords retraction, severely fibrotic and immobile leaflets, severely deformed subvalvular apparatus
  • Evolving endocarditis or active endocarditis in the last 3 months
  • Heavily calcified or dilated annulus or leaflets, mitral valve stenosis
  • Congenital malformation with limited valvular tissue
  • Patient requires mitral valve replacement
  • Evidence of LV or LA thrombus, vegetation or mass
  • Severe tricuspid regurgitation or severe RV dysfunction

Hol van ez a vizsgálat?

3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

A multi-center evaluation of the Pipeline chordal repair system for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve repair.

A vizsgálat csoportja

  • Permanent ImplantA vizsgált kezelés

    Insertion of the Chordal Repair System tethering the mitral leaflets to the left ventricle.

    Kezelés: Transcatheter implantation of chordal repair system

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2024. október 15.